Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. grew its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 69.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 568,845 shares of the company’s stock after acquiring an additional 233,633 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.64% of Kura Oncology worth $6,240,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. IFP Advisors Inc lifted its stake in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the last quarter. Allworth Financial LP increased its position in Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after buying an additional 1,553 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Kura Oncology by 49.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after buying an additional 1,888 shares during the period. Insigneo Advisory Services LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at $105,000. Finally, LPL Financial LLC purchased a new position in shares of Kura Oncology during the 4th quarter valued at $105,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on KURA shares. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Tuesday, July 28th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Sanford C. Bernstein set a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Finally, CLSA set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $9.57 on Monday. Kura Oncology, Inc. has a 52 week low of $5.45 and a 52 week high of $12.49. The business has a 50-day simple moving average of $10.09 and a two-hundred day simple moving average of $9.29. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The company has a market cap of $849.53 million, a P/E ratio of -2.86 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. Research analysts anticipate that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 84,929 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the sale, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.60% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.